ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Real-world treatment outcomes of a 6-month fluoroquinolone-containing regimen for isoniazid mono-resistant pulmonary tuberculosis in Korea.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
purposeProspective real-world evidence on the effectiveness and safety of the World Health Organization-recommended 6-month fluoroquinolone-containing regimen (FqREZ) for isoniazid mono-resistant tuberculosis (Hr-TB) remain limited.
methodsWe conducted a multicenter prospective observational cohort study within the Korean national TB program between 2016 and 2024. Adults with pulmonary Hr-TB received either a 6-month FqREZ or alternative non-FqREZ. The primary outcome was a favorable outcome, defined as treatment success without recurrence within 12 months after treatment completion. The secondary outcome was the occurrence of serious adverse events during treatment. Multivariable logistic regression was performed to assess factors associated with study outcomes.
resultsAmong 99 participants with pulmonary Hr-TB, 55 (55.6%) received FqREZ. Favorable outcomes occurred in 71% with FqREZ and 73% with non-FqREZ (p > 0.99). After adjustment, FqREZ was not associated with a higher likelihood of favorable outcome (adjusted odds ratio, 0.51; 95% confidence interval, 0.17-1.45). No recurrence was identified within 12 months after treatment completion in both treatment groups. Serious adverse events occurred in 29.1% of FqREZ and 20.5% of non-FqREZ recipients (p = 0.361) with hepatobiliary events being most common.
conclusionsIn this prospective real-world cohort, the 6-month FqREZ regimen achieved treatment outcomes comparable to those of non-fluoroquinolone regimens, with a similar safety profile, in pulmonary Hr-TB.
Indexed as
Identifiers
42593593What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.